TABLE 1.
Characteristics of study subjects receiving 1,500 mg of GSK1322322a
| Cohortb | No. of subjects and sexc | Age (yr) | Height (cm) | Wt (kg) | Body mass index (kg/m2) | Total cell count/mm3 in BAL fluid | Macrophages/monocytes (%) |
|---|---|---|---|---|---|---|---|
| 2-hour | 5 M, 1 F | 36.8 ± 13.5 | 181.7 ± 11.5 | 85.4 ± 12.9 | 25.8 ± 2.1 | 102 ± 51 | 86 ± 13 |
| 6-hour | 4 M, 1 F | 37.2 ± 15.0 | 170.4 ± 14.3 | 70.5 ± 14.2 | 24.2 ± 3.7 | 111 ± 26 | 83 ± 8 |
| 12-hour | 3 M, 3 F | 51.3 ± 9.0 | 175.5 ± 2.4 | 78.9 ± 14.2 | 25.5 ± 4.0 | 102 ± 39 | 89 ± 13 |
a
Data are expressed as means ± SD except for sex.
b
Seventeen subjects received multiple i.v. doses of GSK1322322 and had bronchoalveolar lavage fluid collected.
c
M, male; F, female.